Electronic cigarettes pose less danger than traditional smoking

Jul.08.2022
Electronic cigarettes pose less danger than traditional smoking
Evidence shows that vaping is less harmful than smoking and can help smokers quit, but media coverage has hindered public understanding.

The evidence is clear: vaping is less dangerous than smoking and can help many people quit their deadly smoking habit. No public data can refute these two conclusions, but tobacco control researchers, activists, and federal regulatory agencies often deny or downplay these observations. This contaminates the public's understanding of electronic cigarettes and prevents smokers from trying out alternative solutions that could potentially save their lives.


Using electronic cigarettes helped me successfully quit smoking, according to a recent conclusion published in the American Journal of Preventive Medicine. Medscape reported on June 20 that "an increasing number of American adults believe that electronic cigarettes are more harmful than traditional cigarettes.


Why are the public afraid of electronic cigarettes?


The author analyzed data collected as part of the Health Information National Trends Survey (HINTS), which is a nationally representative survey conducted through mail that asks American adults about their attitudes towards cancer and other health-related information. The data was collected over five cycles between January 2018 and May 2020, with over 3000 respondents included in the final analysis each year (3360 in 2018, 3217 in 2019, and 3677 in 2020). The author reports that...


The relative perceived harm of electronic cigarettes versus traditional cigarettes was assessed through the following question with six possible answers: Compared to smoking, would you say that electronic cigarettes are... Respondents were categorized as perceiving electronic cigarettes to be less harmful (less harmful or much less harmful) than traditional cigarettes, equally harmful, or more harmful (more harmful or much more harmful) than traditional cigarettes.


The author suggests that the negative shift in perception may have been driven by the media's coverage of the so-called "EVALI outbreak". From 2019 to 2020, over 2,000 individuals were hospitalized due to e-cigarette related lung injuries and 68 people died.


These cases were not caused by electronic cigarettes themselves, which were mistakenly maintained by the Centers for Disease Control and Prevention for a few months, but by devices purchased illegally for vaping THC or CBD. These chemicals, derived from cannabis rather than tobacco, were mixed with vitamin E acetate which may have contributed to the reported lung injuries. Dr. Josh Bloom provided a helpful explanation of the chemical reaction behind this phenomenon in the story, which subsequent research has confirmed.


During the outbreak of EVALI, journalists did what they often do without having all the facts: they amplified the risk, with the tacit approval of the Centers for Disease Control, but were not interested in reporting on the controversy surrounding the decision. According to the study authors:


In March and April of 2020, there was a high level of harmful relative opinions. This suggests that misunderstandings have persisted since the initial discovery of the connection to vitamin E acetate in September 2019, possibly due to media coverage not remaining at the same level after the source of the epidemic was determined.


The trend is still continuing.


EVALI is no longer a major public health concern, but controversial ideological radicalism and careless reporting continue to undermine electronic cigarettes as a harm reduction tool in today's society. Researchers have published low-quality studies alleging serious health consequences from using e-cigarettes, and the media dutifully reported on these findings. The ACSH and other scientifically-minded media outlets have corrected the propaganda, but unfortunately, this good news has not garnered as much attention as sensational and scary headlines.


Experts recognize the issue and acknowledge the need for a solution. According to a doctor, we are effective at communicating the harmful effects of smoking and the dangers of tobacco in public health. Ashley Brooks-Russell, associate professor at the Colorado School of Public Health, stated to Medscape Medical News that we struggle to discuss smaller choices, such as the lesser harm of e-cigarettes compared to smoking.


Dr. Russell is correct, but I will go even further. Even though researchers have documented the harm caused by common anti-vaping metaphors, tobacco researchers cannot abandon their skepticism of e-cigarettes. As the authors of the study themselves have written,


Electronic cigarettes contain high levels of nicotine and appealing flavors that may lead to addiction and the use of combustible tobacco products among adolescents and young adults.


The sentence is at least partially false. Many electronic cigarettes contain little to no nicotine. Flavored electronic cigarettes do not encourage youth to use any tobacco products, and there is no concrete evidence to support this speculation. The author also reiterated the anti-electronic cigarette stance, which has become a staunch article among tobacco researchers: "The risks associated with long-term use are still unclear." This is undoubtedly true, as no one has a crystal ball, but public health researchers often use such language to suggest that we will discover some serious risks associated with electronic cigarettes in the future.


The American Cancer Society claims that the long-term risks of only using electronic cigarettes are not yet fully clear. However, there is increasing evidence that using e-cigarettes has negative effects on the cardiovascular system and lungs. If immediate action is not taken to stop the widespread use of these products, the long-term adverse health effects will increase.


Can you imagine a large medical institution issuing a statement similar to this regarding the use of COVID-19 vaccines or puberty blockers for treating gender dysphoria? After all, we do not know the potential long-term effects of these powerful drugs on those who take them. Of course, until we have a better understanding of these products, we must halt their "popular use," shouldn't we?


If these issues are frustrating you, then maybe you're starting to understand why the popular rhetoric surrounding e-cigarettes is so absurd. Properly evaluating any product requires accurately balancing its risks and benefits. No one is claiming that e-cigarettes are risk-free; they are an effective intervention aimed at reducing the harm of smoking, which is killing people all over the world.


Given this standard, speculating about potential hazards we may discover one day is a foolish thought exercise. Let the public know what we know today: for adult smokers who want to quit smoking, electronic cigarettes are a low-risk option.


This article is compiled from third-party information and is only intended for educational purposes. The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

DOJ Trade Fraud Task Force Tops $1 Billion in Cases, Putting Vape Supply Chains at Risk of Fraud Enforcement
DOJ Trade Fraud Task Force Tops $1 Billion in Cases, Putting Vape Supply Chains at Risk of Fraud Enforcement
According to the U.S. Department of Justice (DOJ), Fox News and other reports, the DOJ’s Trade Fraud Task Force (TFTF) has been linked to more than $1 billion in recoveries, penalties, forfeitures and publicly charged losses in less than one year. The task force focuses on trade fraud issues including country-of-origin fraud, illegal transshipment, false declarations and tariff evasion. While vape products are not the main source of the $1 billion figure, the industry’s reliance on global manufacturing and cross-border supply chains places it within broader U.S. trade enforcement scrutiny. The development suggests that U.S. oversight of cross-border vape products may increasingly extend beyond product authorization into import compliance, supply-chain transparency and corporate accountability.
Jul.23
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
The U.S. Food and Drug Administration authorized 11 ZYN ULTRA nicotine pouch products made by Swedish Match USA through the premarket tobacco product application pathway on August 21, 2026. Ten of the authorized products have a labeled nicotine content of 9 mg, while ZYN ULTRA Smooth was authorized at 11 mg. The reviews were conducted through FDA’s nicotine pouch PMTA pilot program. FDA has now authorized 43 nicotine pouch products, including 23 through the pilot.
Aug.24
Product | SnowPlus Launches Nicotine-Free DASH in South Korea, Localising an Established Disposable Platform
Product | SnowPlus Launches Nicotine-Free DASH in South Korea, Localising an Established Disposable Platform
SnowPlus has introduced a nicotine-free version of DASH in South Korea, adapting an existing overseas disposable platform for the local market. The Korean version retains the series’ flat duckbill-style mouthpiece, ceramic heating architecture and disposable form factor while reducing nicotine content to 0%. By comparison, the overseas DASH 4000 platform typically features 7.5ml of prefilled e-liquid, up to 4,000 puffs and a 530mAh rechargeable battery, with nicotine-containing variants available in some markets. The product update centers on formulation localisation rather than a new hardware generation.
Aug.31
AIR Invests $20 Million in Greentank, Deepening Capital Ties Across the Vape Supply Chain
AIR Invests $20 Million in Greentank, Deepening Capital Ties Across the Vape Supply Chain
Nasdaq-listed AIR Global has invested $20 million in preferred shares of Canadian vaporization technology company Greentank, deepening a partnership established in 2023. AIR gains a board nomination right, access to new technologies, enhanced commercial terms and long-term supply assurances, while retaining an option to increase its stake. Greentank’s Quantum Chip platform powers Crown Switch and forms part of AIR’s planned U.S. PMTA dossier, linking capital investment more closely with product technology, regulatory evidence and supply-chain control.
Special Report
Jul.29
Product | JNR Launches Shisha Hookah 70K E-Hookah With 60ml E-Liquid and 0.6% Nicotine
Product | JNR Launches Shisha Hookah 70K E-Hookah With 60ml E-Liquid and 0.6% Nicotine
JNR has introduced the Shisha Hookah 70K, a high-capacity rechargeable disposable vape designed around a hookah-inspired experience. The device comes prefilled with 60ml of e-liquid at 6mg/ml (0.6%) nicotine strength, alongside a 1,000mAh rechargeable battery and a 0.38Ω single mesh coil. It also features adjustable airflow and battery and e-liquid level displays. JNR claims the device can deliver up to 70,000 puffs and offers more than 20 flavors. Retail listings for the product have appeared in markets including Tunisia.
Market
Aug.24 by 2Firsts Perspectives
Product | APUS Launches Chloe 50K, Bringing Purse-Inspired Design to the U.S. High-Puff Disposable Market
Product | APUS Launches Chloe 50K, Bringing Purse-Inspired Design to the U.S. High-Puff Disposable Market
APUS has introduced the Chloe 50K disposable vape, which has appeared across U.S.-facing online retail channels including Element Vape and Vapesourcing. The device combines a purse-inspired body and chain attachment with a 20ml e-liquid capacity, 1,250mAh rechargeable battery, dual mesh coil, and battery and e-liquid indicators. It is rated for up to 50,000 puffs. The product does not appear on the FDA’s current list of authorized e-cigarettes, and U.S. retail availability does not indicate FDA marketing authorization.
Jul.15